Centers | ||
test | EU-OPENSCREEN | Saint Louis University Institute for Drug and Biotherapeutic Innovation (IDBI) |
sfgd |
EU-OPENSCREEN is a multinational, not-for-profit initiative, which
integrates high-capacity screening platforms and chemistry groups across
Europe. The aim of this initiative is to support individual scientists
interested in chemical biology... |
The IDBI is a decentralized, collaborative institute whose mission is to promote the translation of research projects at Saint Louis University through drug discovery and pre-clinical development. The IDBI achieves this through four main... |
Partnerships |
Events |
Jobs |
JDRF & Novo Nordisk to Collaborate on Type 1 DiabetesJDRF and Novo Nordisk have entered into collaboration to develop new immunotherapies to treat Type 1 diabetes. The new partnership will be based out of Novo's newly opened Type 1 Diabetes R&D Center in Seattle. JDRF and Novo Nordisk will be... View all Johns Hopkins BSi Licenses GCPII Assets from EisaiJohns Hopkins Brain Science Institute ("BSi") has taken a non-exclusive license from Eisai to develop new compounds related to Glutamate Carboxypeptidase II (GCP-II) technology. The new compounds developed under this license will be targeted... View all CWHM/OWH Childhood DiarrheaCWHM signed a joint research agreement in 2010 with the Institute for One World Health to discover and develop new drugs to combat diarrhea, which is the second leading cause of death worldwide in children under age 5. Under the agreement, CWHM... View all |
No EVENTS for listing |
No Job Posts |


